Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor.

Drugs of today (Barcelona, Spain : 1998)

Isley WL.
PMID: 12743630
Drugs Today (Barc). 2001 Sep;37(9):587-594. doi: 10.1358/dot.2001.37.9.844218.

Pitavastatin calcium (NK-104) is a new synthetic hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin). Animal studies suggest that, in addition to reducing low-density lipoprotein (LDL) cholesterol, the drug may produce marked reductions in triglyceride-rich particles (very-low-density [VLDL] and intermediate-density lipoproteins...

Cite
Isley WL. Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (Barc). 2001;37(9):587-594doi: 10.1358/dot.2001.37.9.844218.
Isley, W. L. (2001). Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs of today (Barcelona, Spain : 1998), 37(9), 587-594. https://doi.org/10.1358/dot.2001.37.9.844218
Isley, William L.. "Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor." Drugs of today (Barcelona, Spain : 1998) vol. 37,9 (2001): 587-594. doi: https://doi.org/10.1358/dot.2001.37.9.844218
Isley WL. Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (Barc). 2001 Sep;37(9):587-594. doi: 10.1358/dot.2001.37.9.844218. PMID: 12743630.
Copy Download .nbib Format: NLM
Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations.

NDT plus

Katayama A, Wada J, Kataoka HU, Yamasaki H, Teshigawara S, Terami T, Inoue K, Kanzaki M, Murakami K, Nakatsuka A, Sugiyama H, Koide N, Bujo H, Makino H.
PMID: 25984174
NDT Plus. 2011 Oct;4(5):299-302. doi: 10.1093/ndtplus/sfr091. Epub 2011 Jul 26.

Familial lecithin:cholesterol acyltransferase deficiency (FLD) is an autosomal recessive disorder characterized by corneal opacity, hemolytic anemia, low high-density lipoprotein cholesterol (HDL-C) and proteinuria. Two novel lecithin:cholesterol acyltransferase (LCAT) mutations[c.278 C>T (p.Pro69Leu); c.950 T>C (p.Met293Thr)] were identified in a 27-year-old...

Cite
Katayama A, Wada J, Kataoka HU, et al. Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations. NDT Plus. 2011;4(5):299-302doi: 10.1093/ndtplus/sfr091.
Katayama, A., Wada, J., Kataoka, H. U., Yamasaki, H., Teshigawara, S., Terami, T., Inoue, K., Kanzaki, M., Murakami, K., Nakatsuka, A., Sugiyama, H., Koide, N., Bujo, H., & Makino, H. (2011). Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations. NDT plus, 4(5), 299-302. https://doi.org/10.1093/ndtplus/sfr091
Katayama, Akihiro, et al. "Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations." NDT plus vol. 4,5 (2011): 299-302. doi: https://doi.org/10.1093/ndtplus/sfr091
Katayama A, Wada J, Kataoka HU, Yamasaki H, Teshigawara S, Terami T, Inoue K, Kanzaki M, Murakami K, Nakatsuka A, Sugiyama H, Koide N, Bujo H, Makino H. Two novel mutations of lecithin:cholesterol acyltransferase (LCAT) gene and the influence of APOE genotypes on clinical manifestations. NDT Plus. 2011 Oct;4(5):299-302. doi: 10.1093/ndtplus/sfr091. Epub 2011 Jul 26. PMID: 25984174; PMCID: PMC4421733.
Copy Download .nbib Format: NLM
Mode of action and adverse effects of lipid lowering drugs.

Drugs of today (Barcelona, Spain : 1998)

Eghdamian B, Ghose K.
PMID: 14743263
Drugs Today (Barc). 1998 Nov;34(11):943-56. doi: 10.1358/dot.1998.34.11.487479.

Serum lipids, cholesterol and triglycerides are incorporated into hydrophilic lipoproteins, which include chylomicrons, very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins (HDL). An elevated level of these lipoproteins, except for...

Cite
Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc). 1998;34(11):943-56doi: 10.1358/dot.1998.34.11.487479.
Eghdamian, B., & Ghose, K. (1998). Mode of action and adverse effects of lipid lowering drugs. Drugs of today (Barcelona, Spain : 1998), 34(11), 943-56. https://doi.org/10.1358/dot.1998.34.11.487479
Eghdamian, B, and Ghose, K. "Mode of action and adverse effects of lipid lowering drugs." Drugs of today (Barcelona, Spain : 1998) vol. 34,11 (1998): 943-56. doi: https://doi.org/10.1358/dot.1998.34.11.487479
Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc). 1998 Nov;34(11):943-56. doi: 10.1358/dot.1998.34.11.487479. PMID: 14743263.
Copy Download .nbib Format: NLM
Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis.

Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion

Castillo-Núñez Y, Morales-Villegas E, Aguilar-Salinas CA.
PMID: 34759386
Rev Invest Clin. 2021 Nov 10; doi: 10.24875/RIC.21000416. Epub 2021 Nov 10.

The term "triglyceride-rich lipoproteins" (TRLs) includes chylomicrons and their remnants, very low-density lipoproteins (VLDL), and intermediate-density lipoproteins (IDL). In this manuscript, the mechanisms by which atherogenic TRLs contribute to the formation of atheroma plaques are reviewed. Cholesterol from TRLs...

Cite
Castillo-Núñez Y, Morales-Villegas E, Aguilar-Salinas CA. Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Rev Invest Clin. 2021;doi: 10.24875/RIC.21000416.
Castillo-Núñez, Y., Morales-Villegas, E., & Aguilar-Salinas, C. A. (2021). Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, . https://doi.org/10.24875/RIC.21000416
Castillo-Núñez, Yulino, et al. "Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis." Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion vol. (2021). doi: https://doi.org/10.24875/RIC.21000416
Castillo-Núñez Y, Morales-Villegas E, Aguilar-Salinas CA. Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis. Rev Invest Clin. 2021 Nov 10; doi: 10.24875/RIC.21000416. Epub 2021 Nov 10. PMID: 34759386.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries